Rocket Pharmaceuticals reports favorable early safety in the pivotal Phase 2 RP-A501 trial for Danon disease, with no TMA or capillary leak syndrome observed.
Written By: Shaik Yasmeen, PharmD
Reviewed By: Pharmacally Editorial Team
Rocket Pharmaceuticals has reported encouraging early safety data from the first three patients treated with its investigational gene therapy RP-A501 under a modified protocol in the global pivotal Phase 2 trial for Danon disease. The absence of thrombotic microangiopathy (TMA), capillary leak syndrome, and other major safety events supports continued regulatory discussions as the company works with the US Food and Drug Administration (FDA) toward completing the pivotal study.
Rocket Pharmaceuticals has safely treated the first three participants enrolled under the revised Phase 2 protocol evaluating RP-A501 for Danon disease, marking an important step in restarting clinical development after protocol modifications. Based on these initial findings, the company is actively engaging with the FDA to finalize the regulatory pathway for enrolling additional patients and completing the pivotal trial. A broader program update is expected during the second half of 2026.
RP-A501 Targets the Genetic Cause of Danon Disease
RP-A501 is an investigational adeno-associated virus serotype 9 (AAV9)-based gene therapy that delivers a functional copy of the LAMP2B gene through a single intravenous infusion. The therapy is intended to restore lysosome-associated membrane protein 2B (LAMP2B) function, correcting the underlying genetic defect responsible for Danon disease.
Danon disease is a rare X-linked lysosomal disorder caused by mutations in the LAMP2 gene. Defective autophagy leads to the accumulation of glycogen and autophagosomes, particularly in cardiac muscle, resulting in progressive cardiomyopathy, heart failure, skeletal muscle involvement, and neurological manifestations. Male patients often experience rapid disease progression, with many requiring heart transplantation during adolescence or early adulthood. Cardiac transplantation remains the only definitive treatment but is not curative.
RP-A501 has received multiple expedited regulatory designations, including FDA Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Rare Pediatric Disease, and Orphan Drug designations, as well as Advanced Therapy Medicinal Product (ATMP) and PRIME designations in Europe.
Modified Phase 2 Protocol Shows Encouraging Early Safety
The pivotal Phase 2 study (NCT06092034) is a single-arm trial planned to enroll 12 patients with Danon disease.
The first three participants received RP-A501 at a recalibrated dose of 3.8 × 10¹³ genome copies (GC)/kg together with a refined immunomodulatory regimen consisting of rituximab, sirolimus, and corticosteroids. Patients were dosed sequentially, with at least four weeks separating each infusion.
According to Rocket Pharmaceuticals, none of the treated patients has experienced thrombotic microangiopathy, capillary leak syndrome, or other clinically significant safety concerns to date. These early observations support the modified dosing strategy and updated immune suppression regimen introduced after previous safety evaluations.
The recalibrated dose reflects the higher proportion of full viral capsids in the current manufacturing process while aiming to maintain the therapeutic activity previously observed in the Phase 1 study.
Leadership Highlights Confidence in Updated Development Strategy
Chief Executive Officer Gaurav Shah, MD, said the favorable early safety findings reinforce confidence in RP-A501 following the transformative results previously reported in the Phase 1 trial. He noted that the company is working closely with the FDA to establish the most efficient path for completing the pivotal Phase 2 study.
Chief Medical Officer Syed Rizvi, MD, explained that the revised dose was selected to preserve efficacy while improving the therapy’s benefit-risk profile. He added that the updated protocol was developed in consultation with leading clinical experts and the FDA to account for manufacturing improvements that increased the proportion of functional viral capsids.
Regulatory Discussions Continue as Program Advances
Rocket Pharmaceuticals expects to provide a comprehensive update on the Danon disease program during the second half of 2026, including progress on regulatory alignment and the next phase of patient enrollment.
If discussions with the FDA proceed as planned, completion of the pivotal Phase 2 study could position RP-A501 as one of the first gene therapies targeting an inherited cardiovascular disorder. Positive results from the remaining patients would strengthen the evidence supporting RP-A501 as a potential disease-modifying treatment for Danon disease, an area where effective therapeutic options remain extremely limited.
Reference
About the Writer
Shaik Yasmeen (LinkedIn) is a Pharm.D graduate with interests in clinical pharmacy, pharmacovigilance, and medical writing. She has gained experience through hospital clinical postings, patient case reviews, case presentations, and literature evaluation. Passionate about evidence-based healthcare, she is committed to creating accurate and engaging medical content while continuously expanding her professional knowledge.